All Data
Sanofi Active Ingredient Solutions cover both APIs sales & CDMO.
Lead Product(s): Isatuximab,Carfilzomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Sarclisa
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2021
Details:
CHMP issues positive opinion for second indication for Sarclisa in combination with carfilzomib and dexamethasone for adult patients with multiple myeloma who have received at least one prior therapy.
Sanofi Active Ingredient Solutions cover both APIs sales & CDMO.
Lead Product(s): Isatuximab,Carfilzomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2020
Details:
Sarclisa added to carfilzomib and dexamethasone (Sarclisa combination) reduced risk of disease progression or death by 47% versus standard of care carfilzomib and dexamethasone (Kd) alone.
Sanofi Active Ingredient Solutions cover both APIs sales & CDMO.
Lead Product(s): Isatuximab,Carfilzomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2020
Details:
Addition of Sarclisa significantly reduced the risk of disease progression or death compared to carfilzomib and dexamethasone alone.
Sanofi Active Ingredient Solutions cover both APIs sales & CDMO.
Lead Product(s): Cemiplimab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2020
Details:
Protocol-specified interim analysis conducted by the Independent Data Monitoring Committee demonstrated that patients treated with Libtayo monotherapy had a significant increase in overall survival.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Monalizumab,Cetuximab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca PLC
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Agreement October 23, 2020
Details:
Monalizumab, Innate’s lead partnered asset. On April 24, 2015, Innate signed a co development and commercialization agreement with AstraZeneca to accelerate and broaden the development of monalizumab.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tedopi
Therapeutic Area: Oncology Product Name: OSE-2101
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2020
Details:
The primary endpoint, 1-year overall survival rate in the mITT** population, was achieved in patients treated with Tedopi®.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cabozantinib,Nivolumab
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2020
Details:
Presentations will feature promising data across multiple cancers, including renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, prostate cancer and various neuroendocrine tumors.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tedopi
Therapeutic Area: Oncology Product Name: OSE-2101
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2020
Details:
Step-1 results of OSE Immunotherapeutics' Phase 3 clinical trial of investigational product Tedopi®, called Atalante 1, in HLA-A2 positive non-small cell lung cancer patients after failure from immune checkpoint inhibitors will be presented at the ESMO Virtual Congress 2020.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cabozantinib,Atezolizumab
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Exelixis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 02, 2020
Details:
Ipsen will join the Exelixis and Roche clinical collaboration and participate in the funding of the recently initiated CONTACT-01 and CONTACT-02 global Phase III pivotal trials.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Irinotecan,Oxaliplatin,Leucovorin
Therapeutic Area: Oncology Product Name: Onivyde
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2020
Details:
Ipsen has initiated the NAPOLI-3 Phase III clinical study (NCT04083235) comparing the safety and efficacy of liposomal irinotecan + 5 fluorouracil/leucovorin (5-FU/LV) + oxaliplatin (OX) (NALIRIFOX) to gemcitabine + nab-paclitaxel in the first-line setting.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
